Synonyms: compound 4 [PMID: 25850459] | JNJ-39439335 | JNJ39439335
Compound class:
Synthetic organic
Comment: Mavatrep (JNJ-39439335) is a TRPV1 antagonist that was designed for analgesic potential [3].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Mavatrep (JNJ-39439335) was advanced to clinical trials. An efficacy signal that was demonstrated in phase 1 study participants with osteoarthritis pain [1] needs to be confirmend in larger phase 2 studies. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00933582 | A Clinical Study to Investigate the Effect on Pain Relief of a Single Dose of JNJ-39439335 in Patients With Chronic Osteoarthritis Pain of the Knee | Phase 1 Interventional | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | ||
NCT01631487 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants | Phase 1 Interventional | Janssen Research & Development, LLC | 2 | |
NCT01343303 | A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis | Phase 1 Interventional | Janssen Research & Development, LLC | 1 |